KeifeRx is building upon its extensive clinical experience in neurodegenerative diseases to advance a second generation of orally delivered small molecules that demonstrate high blood-brain-barrier penetration, selective kinase inhibition, and enhanced clearance of toxic protein buildup associated with neurodegenerative disease.  Additionally, selective inhibition of kinases related to mast cell-mediated inflammatory conditions has the potential to reduce symptoms for patients suffering from immune conditions.